Skip to main content
SpringerLink
Log in

Obsessive-Compulsive Disorder in Elderly Patients

  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Obsessive-compulsive disorder (OCD) is a common illness which starts in young adulthood and persists into late life. OCD is associated with dysregulation of the serotonin system and may also be related to the dysregulation of dopamine. When OCD starts in an elderly patient, either an organic or a neurological diagnosis should be considered.

Clomipramine and serotonin reuptake inhibitors are the mainstay of treatment for OCD. Choice of a particular agent should be based on the patient’s previous response and the adverse effect profile of the drug. Pharmacokinetics should also be a consideration due to age-related changes in hepatic and renal function leading to increased plasma concentrations as well as prolonged elimination half-lives of these agents. Behavioural therapy, in addition to pharmacological management, is essential to treat compulsions and to improve response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jenike MA. Geriatric obsessive-compulsive disorder. J Geriatr Psychiatry Neurol 1991; 4: 34–9

    PubMed  CAS  Google Scholar 

  2. Robins LN, Heizer JI, Weissman MM, et al. Lifetime prevalence of psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58

    PubMed  CAS  Google Scholar 

  3. Thyer BA, Parrish RT, Curtis GC, et al. Ages of onset of DSM III anxiety disorders. Compr Psychiatry 1985; 26: 113–22

    PubMed  CAS  Google Scholar 

  4. Regier DA, Boyd JH, Burke Jr JD, et al. One month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45: 977–86

    PubMed  CAS  Google Scholar 

  5. Eaton WW, Kramer M, Anthony JC, et al. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area program. Acta Psychiatr Scand 1989; 79: 163–78

    PubMed  CAS  Google Scholar 

  6. Zak JP, Miller JA, Sheehan DV, et al. The potential role of the serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1988; 49: 23–9

    PubMed  Google Scholar 

  7. Austin LS, Lydiard RB, Ballenger JC, et al. Dopamine blocking activity in clomipramine patients with obsessive-compulsive disorder. Biol Psychiatry 1991; 30: 225–32

    PubMed  CAS  Google Scholar 

  8. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry 1990; 51 Suppl.: 36–43

    PubMed  Google Scholar 

  9. Black D. Family study of obsessive-compulsive disorder. Read before the Annual Meeting of the Psychiatic Research Society: 1991 Feb 13–16; Park City, Utah

  10. Shilder P. The organic background of obsessions and compulsions. Am J Psychiatry 1938; 94: 1397–416

    Google Scholar 

  11. Wright M, Hewlett WA. Neurobioloy of obsessive-compulsive disorder. Compr Ther 1994; 20: 95–100

    PubMed  CAS  Google Scholar 

  12. McGuire PK, Bench CJ, Frith CD, et al. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994; 164: 459–68

    PubMed  CAS  Google Scholar 

  13. Baxter LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681–9

    PubMed  CAS  Google Scholar 

  14. Abbruzzese M, Bellodi L, Ferri S, et al. Frontal lobe dysfunction in schizophrenia and obsessive-compulsive disorder: a neuropsychological study. Brain Cogn 1995; 27: 202–12

    PubMed  CAS  Google Scholar 

  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 417–23

    Google Scholar 

  16. Rasmussen S, Tsuang M. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 1986; 143: 317–22

    PubMed  CAS  Google Scholar 

  17. Akhtar S, Wig NN, Varma VK, et al. A phenomenologic analysis of symptoms in obsessive-compulsive neurosis. Br J Psychiatry 1975; 127: 342–8

    PubMed  CAS  Google Scholar 

  18. Marks IM. Behavioral psychotherapy. Maudsley pocketbook of clinical management. London: Butterworth, 1986

    Google Scholar 

  19. Veale D. Classification and treatment of obsessional slowness. Br J Psychiatry 1993; 162: 198–203

    PubMed  CAS  Google Scholar 

  20. Helzer JE, Pryzbek TR. The co-occurence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988; 49: 219–24

    PubMed  CAS  Google Scholar 

  21. Gerber PD, Barrett J, Manheimer E, et al. Recognition of depression by internists in primary care: a comparison of internists and ‘gold standard’ psychiatric assessments. J Gen Intern Med 1989; 4: 7–13

    PubMed  CAS  Google Scholar 

  22. Keller MB. Depression. Underrecognition and undertreatment by psychiatrists and other health care professionals. Arch Intern Med 1990; 150: 946–8

    PubMed  CAS  Google Scholar 

  23. Austin LS, Lydiard RB, Fossey MD, et al. Panic and phobic disorders in patients with obsessive-compulsive disorder. J Clin Psychiatry 1990; 51: 456–8

    PubMed  CAS  Google Scholar 

  24. Kunik ME, Pollock BG, Perel JM, et al. Clomipramine in the elderly: tolerance and plasma levels. J Geriatr Psychiatry Neurol 1994; 7: 139–43

    PubMed  CAS  Google Scholar 

  25. Asberg M, Ringberger VA, Sjovist F, et al. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther 1977; 21: 201–7

    PubMed  CAS  Google Scholar 

  26. Traskman L, Asberg M, Bertilsson L, et al. Plasma levels of chlorimipramine and its desmethyl metabolite during the treatment of depression. Clin Pharmacol Ther 1979; 26: 600–10

    PubMed  CAS  Google Scholar 

  27. Stern RS, Marks IM, Mawson D, et al. Clomipramine and exposure for compulsive rituals: II. Plasma level, outcomes and side effects. Br J Psychiatry 1980; 136: 161–6

    PubMed  CAS  Google Scholar 

  28. Kasvikis Y, Marks IM. Clomipramine in obsessive-compulsive ritualizers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects. Psychopharmacology 1988; 95: 113–8

    PubMed  CAS  Google Scholar 

  29. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exper Ther 1985; 232: 183–8

    CAS  Google Scholar 

  30. Burch JE, Shaw DM, Michalakeas A, et al. Time course of plasma drug levels during once-daily oral administration of clomipramine. Psychopharmacology 1982; 77: 344–7

    PubMed  CAS  Google Scholar 

  31. Ciba Pharmaceutical Co. Anafranil package insert. Summit, NJ: Ciba Pharmaceutical Co., 1990

    Google Scholar 

  32. Burchinsky SG. Neurotransmitter receptors in the central nervous system and aging: pharmacological aspect [review]. Exp Gerontol 1984; 19: 227–39

    PubMed  CAS  Google Scholar 

  33. Davis P. Studies on the neurochemistry of cholinergic systems in Alzheimer’s disease. Aging 1978: 7: 453–9

    Google Scholar 

  34. Boston Collaborative Drug Surveillance Program. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. N Engl J Med 1973: 288: 277–80

    Google Scholar 

  35. Blake AJ, Morgan K, Bindall MJ, et al. Falls by elderly people at home: prevalance and associated factors. Age Ageing 1988; 17: 365–72

    PubMed  CAS  Google Scholar 

  36. Caird FI, Andrews GR, Kennedy RD. Effect of posture on blood pressure in the elderly. Br Heart J 1973; 35: 527–30

    PubMed  CAS  Google Scholar 

  37. Ray WA, Griffen MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 303–9

    Google Scholar 

  38. Deveaugh-Geiss J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in OCD. Psychopharmacol Bull 1989; 25: 36–40

    PubMed  CAS  Google Scholar 

  39. Anafranil unanimously claimed for approval by Advisory Committee: review comes 4½ months after NDA filing. FDC Reports (‘The Pink Sheet’); 1989 Dec: 3–4

  40. Monteiro WO, Noshirvani HF, Marks IM, et al. Anorgasmia from clomipramine in obsessive-compulsive disorder. Br J Psychiatry 1987; 151: 107–12

    PubMed  CAS  Google Scholar 

  41. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508

    PubMed  CAS  Google Scholar 

  42. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34

    PubMed  CAS  Google Scholar 

  43. Heym J, Koe BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49 (Suppl. 8): 40–5

    PubMed  Google Scholar 

  44. Dechant KI, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 1991; 41: 225–53

    PubMed  CAS  Google Scholar 

  45. Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1986; 6: 98–101

    PubMed  CAS  Google Scholar 

  46. Fontaine R, Chouinard G. Fluoxetine in the long term maintenance treatment of obsessive-compulsive disorder. Psychiatr Ann 1989; 19: 88–91

    Google Scholar 

  47. Jenike MA, Buttolph L, Baer L, et al. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1989; 146: 909–11

    PubMed  CAS  Google Scholar 

  48. Liebowitz MR, Hollander E, Schneier F, et al. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol 1989; 9: 423–7

    PubMed  CAS  Google Scholar 

  49. Turner SM, Jacob RG, Beidel DC, et al. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1985; 5: 207–12

    PubMed  CAS  Google Scholar 

  50. Pigott TA, Pato MT, Bernstein SC, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 926–32

    PubMed  CAS  Google Scholar 

  51. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed dose fluoxetine in the treatment of OCD. Arch Gen Psychiatry 1994; 51: 559–67

    PubMed  CAS  Google Scholar 

  52. Aronoff GR, Bergstrom RE, Pothatz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36: 138–44

    PubMed  CAS  Google Scholar 

  53. Wernike JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 59–67

    Google Scholar 

  54. Buff DD, Brenner R, Kirtane SS, et al. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52: 174–6

    PubMed  CAS  Google Scholar 

  55. Aranow RB, Hudson JI, Pope HG, et al. Elevated plasma anti-depressant levels after addition of fluoxetine. Am J Psychiatry 1989; 146:911–3

    PubMed  CAS  Google Scholar 

  56. Downs JM, Downs AD, Rosenthal TL, et al. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. J Clin Psychiatry 1989; 50: 226–7

    PubMed  CAS  Google Scholar 

  57. Weilberg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50: 447–9

    Google Scholar 

  58. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10: 48–50

    PubMed  CAS  Google Scholar 

  59. Pope HG, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988; 145: 1292–4

    PubMed  Google Scholar 

  60. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989; 146: 278

    PubMed  CAS  Google Scholar 

  61. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 1989; 146: 1515

    PubMed  CAS  Google Scholar 

  62. Tate JL. Extrapyramidal symptoms in a patient taking Haldol and fluoxetine [letter]. Am J Psychiatry 1989; 146: 399–400

    PubMed  CAS  Google Scholar 

  63. Bouchard RH, Pourcher G, Vincent P. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1352–3

    Google Scholar 

  64. Brod TM. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1353

    Google Scholar 

  65. Jenike MA, Baer L, Summergrad P, et al. Sertraline in obsessive-compulsive disorder: a double blind comparison with placebo. Am J Psychiatry 1990; 147: 923–8

    PubMed  CAS  Google Scholar 

  66. Chouinard G, Goodman W, Griest J, et al. Results of a double-blind, placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26: 279–84

    PubMed  CAS  Google Scholar 

  67. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 289–95

    PubMed  CAS  Google Scholar 

  68. Roerig Division of Pfizer Pharmaceuticals. Sertraline hydrochloride package insert. New York: Pfizer Pharmaceuticals, 1992

    Google Scholar 

  69. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49: 46–51

    PubMed  Google Scholar 

  70. Conn CK, Shrivastava R, Mendels J, et al. Double-blind multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1991; 51: 12 Suppl. B: 28–33

    Google Scholar 

  71. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo and amitripty-line controlled multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1991; 51: 12 Suppl. B: 18–27

    Google Scholar 

  72. Kaye NS, Dancu C. Paroxetine and obsessive-compulsive disorder. Am J Psychiatry 1994; 151: 1523

    PubMed  CAS  Google Scholar 

  73. Keutheu NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14: 206–7

    Google Scholar 

  74. Price LH, Goodman WK, Charney DS, et al. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987; 144: 1059–61

    PubMed  CAS  Google Scholar 

  75. Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987; 1543–8

  76. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry 1989; 46: 36–44

    PubMed  CAS  Google Scholar 

  77. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147:1209–15

    PubMed  CAS  Google Scholar 

  78. Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994; 55: 301–5

    PubMed  CAS  Google Scholar 

  79. Stern TA, Jenike MA. Treatment of obsessive-compulsive disorder with lithium carbonate. Psychosomatics 1983; 24: 671–3

    PubMed  CAS  Google Scholar 

  80. Forssman H, Walinder J. Lithium treatment on atypical indication. Acta Psychiatr Scand 1969; 207 Suppl.: 34–40

    Google Scholar 

  81. Van Putten T, Sanders DG. Lithium in treatment failures. J Nerv Ment Dis 1975; 161:255–64

    PubMed  Google Scholar 

  82. Hesso OC, Thoreil LH. Lithium and obsessive-compulsive neurosis. a double blind crossover clinical pilot trial. Neuro Psykiatr Tidsskr 1978; 23: 496–9

    Google Scholar 

  83. Geisler A, Schou M. Lithium treatment of obsessive-compulsive neurosis: a double blind crossover clinical pilot trial. Nord Psykiatr Tidsskr 1970; 23: 493–5

    Google Scholar 

  84. Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990: 13: 322–8

    PubMed  CAS  Google Scholar 

  85. Prasad A. Efficacy of trazodone as an antiobsessional agent. Pharmacol Biochem Behav 1985; 22: 347–8

    PubMed  CAS  Google Scholar 

  86. Baxter LR. Two cases of obsessive-compulsive disorder with depression responsive to trazodone. J Nerv Ment Dis 1985; 128: 432–3

    Google Scholar 

  87. Lydiard RB. Obsessive-compulsive disorder successfully treated with trazodone. Psychosomatics 1986; 27: 858–9

    PubMed  CAS  Google Scholar 

  88. Jenike MA, Baer L. An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1285–6

    PubMed  CAS  Google Scholar 

  89. Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127–9

    PubMed  CAS  Google Scholar 

  90. O’Regan JB. Treatment of obsessive-compulsive neurosis with haloperidol. Can Med Assoc J 1970; 103: 167–8

    PubMed  Google Scholar 

  91. Trethowan WH, Scott PA. Chlorpromazine in obsessive-compulsive neurosis and allied disorders. Lancet 1955; i: 781–5

    Google Scholar 

  92. Hussain MZ, Ahad A. Treatment of obsessive-compulsive neurosis. Can Med Assoc J 1970; 103: 648–50

    PubMed  Google Scholar 

  93. McDougle CJ, Goodman WK, Price LH. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 652–7

    PubMed  CAS  Google Scholar 

  94. Jenike MA, Brotman AW. The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984; 45: 122–4

    PubMed  CAS  Google Scholar 

  95. Jain VK, Swinson RP, Thomas JE. Phenelzine in obsessional neurosis. Br J Psychiatry 1970; 237–8

  96. Isberg RS. A comparison of phenelzine and imipramine in an obsessive-compulsive patient. Am J Psychiatry 1980; 138: 1250–1

    Google Scholar 

  97. Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette syndrome: double blind study using objective rating methods. Ann Neurol 1987; 21: 307–10

    PubMed  CAS  Google Scholar 

  98. Knesevich JW. Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride. Am J Psychiatry 1982; 139: 364–5

    PubMed  CAS  Google Scholar 

  99. Lipsedge MS, Prothero W. Clonidine and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 965–6

    PubMed  CAS  Google Scholar 

  100. Bodkin JA, White K. Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989; 50: 265–6

    PubMed  CAS  Google Scholar 

  101. Hollander E, Liebowitz MR. Augmentation of antiobsessional treatment with fenfluramine. Am J Psychiatry 1988; 145: 1314–5

    PubMed  CAS  Google Scholar 

  102. Marks IM, Stern RF, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980; 136: 1–25

    PubMed  CAS  Google Scholar 

  103. Thoren P, Asberg M, Chronholm B, et al. Clomipramine treatment of OCD: a controlled clinical trial. Arch Gen Psychiatry 1980; 93: 1281–5

    Google Scholar 

  104. Pato MA, Zohar-Kadouch R, Zohar J. Return of the symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1521–5

    PubMed  CAS  Google Scholar 

  105. March JS, Johnston H, Griest JH. Obsessive-compulsive disorder. Am Fam Physician 1989; 39: 175–82

    PubMed  CAS  Google Scholar 

  106. Foa EB, Kozak MJ. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Br J Clin Psychol 1992; 31: 279–92

    PubMed  Google Scholar 

  107. O’Sullivan G, Noshirvani H, Marks I, et al. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry 1991; 52: 150–5

    PubMed  Google Scholar 

  108. Jackson CW, Morton WA, Lydiard RB. Pharmacologic management of obsessive-compulsive disorder. South Med J 1994; 87:310–21

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3 North, Institute of Psychiatry, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina, 29425, USA

    Cherry W. Jackson

Authors
  1. Cherry W. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, C.W. Obsessive-Compulsive Disorder in Elderly Patients. Drugs & Aging 7, 438–448 (1995). https://doi.org/10.2165/00002512-199507060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199507060-00004

Keywords

Search

Navigation